Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,927 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 76 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more

Conditions: HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
Interventions: Panitumumab-IRDye800, [18F]NOTA-ABY-030; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin degludec, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 146
States / cities: Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more

Conditions: Lung Cancer
Interventions: filgrastim, carboplatin, topotecan hydrochloride, WBRT; Biological · Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 23
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: ALS-008176, Placebo; Drug
Lead sponsor: Alios Biopharma Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 11
States / cities: Eustis, Florida • Hialeah, Florida • Miami, Florida + 8 more

Conditions: Diabetes Mellitus, Type 1
Interventions: controlled-release oral alpha-lipoic acid; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 110 Years
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 42
States / cities: Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more

Conditions: Iron Deficiency Anemia of Pregnancy
Interventions: Venofer 200 MG Per 10 ML Injection, Ferrous sulfate; Drug
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Colton, California

Conditions: HIV Infections, Pregnancy
Interventions: Nelfinavir mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 7
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Diabetes
Interventions: Oral Glucose Tolerance Test; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Periodontal Diseases
Interventions: Periodontal Treatment; Procedure
Lead sponsor: The Forsyth Institute; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking, Alcohol Drinking, Prescription Drug Abuse, Substance-Related Disorders, Oral Intake Reduced
Interventions: Person-centered inhibitory control training, Active behavioral response training; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 35 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Schizophrenia
Interventions: Lu AF35700; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Gingivitis, Dental Plaque
Interventions: Next Science OTC Oral Rinse with Essential Oils, OTC Oral Rinse Control; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride, temozolomide, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Stanford, California + 13 more

Conditions: Advanced Cancer, Refractory Cancer, Tumor Gastric
Interventions: PCS6422 and capecitabine; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Omaha, Nebraska • New Brunswick, New Jersey • Santa Fe, New Mexico + 3 more

Conditions: COVID-19
Interventions: Emetine Hydrochloride, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Toxic Epidermal Necrolysis
Interventions: Clobetasol 0.05% ointment, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 7 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hyperglycemia
Interventions: Oral water, Intravenous normal saline; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
Interventions: 5-Fluorouracil; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3447; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more

Conditions: Cardiomyopathy, Hypertrophic
Interventions: LCZ696, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Oropharyngeal Cancer, Human Papilloma Virus
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C, Sapacitabine, Arm D, sapacitabine, Arm E, sapacitabine, Arm F, Sapacitabine, Arm G, Sapacitabine, Arm H, Sapacitabine, Arm I; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 10 more

Search by objective public record fields.

Vancomycin for Primary Sclerosing Cholangitis

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Integrated Cancer Repository for Cancer Research

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Pharmacogenetics of Response to Sitagliptin (PRS)

Study Comparing Two Different Methods of Treating Periodontal Disease

Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

Next Science Antimicrobial Mouth Rinse Study

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Evaluating Emetine for Viral Outbreaks (EVOLVE)

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Men and Women Offering Understanding of Throat HPV

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients